Consistent with the findings derived from E2-treated p18−/−;Brca1MGKO and p16−/−;Brca1MGKO tumors, we also found that BRCA1 mutant PDX tumor development was significantly enhanced by E2 treatment relative to that by placebo (Fig. 1c). Here, BRCA1 is linked to neoplasm.